SARS-CoV-2 caused a surge in antibiotic consumption causing a silent pandemic inside the pandemic. A retrospective analysis of Italian data in the first half of 2022

Article Immunology

A short focus, azithromycin in the treatment of respiratory viral infection COVID-19: efficacy or inefficacy?

Antonio Vitiello et al.

Summary: Azithromycin may have some benefits for viral respiratory tract infections like COVID-19, but its antiviral efficacy is uncertain based on clinical data. Additionally, there are risks of causing arrhythmias with Azithromycin.

IMMUNOLOGIC RESEARCH (2022)

添加到收藏夹

Letter Medicine, General & Internal

COVID-19 pandemic: vaccine and new monoclonal antibodies, point of view

Antonio Vitiello et al.

IRISH JOURNAL OF MEDICAL SCIENCE (2022)

添加到收藏夹

Review Pharmacology & Pharmacy

Pandemic COVID-19, an update of current status and new therapeutic strategies

Antonio Vitiello et al.

Summary: The global COVID-19 pandemic continues to spread, with a rapid increase in infections in countries, particularly in Europe, likely due to the new Omicron variant of SARS-CoV-2. Mass vaccination efforts are ongoing worldwide. Oral antiviral drugs such as molnupiravir and paxlovid have shown promising results in clinical trials, but their impact on the pandemic and their advantages over other antivirals like remdesivir need further investigation.

NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

COVID-19 mRNA Vaccines: A Retrospective Observational Pharmacovigilance Study

Francesco Ferrara et al.

Summary: This retrospective pharmacovigilance study demonstrates that COVID-19 mRNA vaccines are safe in all population groups.

CLINICAL DRUG INVESTIGATION (2022)

添加到收藏夹

Article Immunology

Nirmatrelvir-remdesivir association for non-hospitalized adults with COVID-19, point of view

Francesco Ferrara et al.

Summary: The scientific community is actively searching for new antiviral drugs and therapies to combat SARS-CoV-2. Paxlovid, an oral antiviral, has recently been authorized and has shown good efficacy in reducing the risk of hospitalization in COVID-19 patients. Remdesivir is another authorized antiviral for treating SARS-CoV-2 infection. However, there is still limited data in the literature regarding the safety profile and risk of generating antiviral-resistant variants. This manuscript discusses the monotherapy use of paxlovid and remdesivir, as well as the scientific hypothesis of combining nirmatrelvir and remdesivir to increase treatment efficacy, reduce adverse reactions, and prevent antiviral drug resistance.

INFLAMMOPHARMACOLOGY (2022)

添加到收藏夹

Article Public, Environmental & Occupational Health

Antimicrobial Resistance Threats in the emerging COVID-19 pandemic: Where do we stand?

Soumya Ghosh et al.

Summary: During the COVID-19 pandemic, misuse of antibiotics can have disastrous effects on antimicrobial resistance management and antibiotic stewardship programs, especially for patients with bacterial coinfections. Proper control policies and prioritization of antibiotic stewardship plans are crucial in regions with high levels of AMR.

JOURNAL OF INFECTION AND PUBLIC HEALTH (2021)

添加到收藏夹

Review Pharmacology & Pharmacy

Novel Strategy to Combat Antibiotic Resistance: A Sight into the Combination of CRISPR/Cas9 and Nanoparticles

Fen Wan et al.

Summary: Antibiotic resistance poses a significant global health crisis, and the combination of CRISPR/Cas9 gene-editing tools and nanotechnology offers a potential solution to combat multidrug-resistant bacterial infections.

PHARMACEUTICS (2021)

添加到收藏夹

Article